Monitor next quarterly filing for contribution of Bridgewell revenue/EBITDA and impact on Vireo's consolidated leverage. The convertible notes cannot convert until the 2nd anniversary (June 2028), so near-term dilution is limited. Watch for regulatory approvals on Nevada and Maryland dispensary deals. The conflict of interest (CEO Mazarakis is a partner at lender Chicago Atlantic) may draw shareholder scrutiny.
Price Chart
Executive Summary
Vireo Growth Inc. closed the acquisition of Bridgewell Agribusiness LLC on June 5, 2026 for approximately $13.66 million in unsecured subordinated convertible notes, plus the assumption of ~$30.35 million in existing indebtedness. Consideration includes convertible notes with 3.85% interest, 5-year maturity, convertible at $0.62/share into an estimated 22 million subordinate voting shares. Separately, Vireo announced two small pending dispensary acquisitions in Nevada and Maryland. The deal significantly increases Vireo's leverage but adds organic food supply chain capabilities, while the CEO's affiliation with the largest debt holder (Chicago Atlantic) raises governance considerations.
Key Financial Metrics
Key Facts
- Base purchase price of $40M adjusted to ~$13.66M closing purchase price, paid via convertible notes
- Assumed ~$30.35M in total debt, including $22M senior secured loan from Chicago Atlantic (affiliate of CEO John Mazarakis)
- Convertible notes aggregate ~$13.66M at 3.85% interest, maturing in 5 years, convertible at $0.62/share for ~22M shares
- Bridgewell is an organic/non-GMO food ingredient supply chain business — not cannabis
- Two pending dispensary acquisitions: Nevada ($500k total, $290k cash + stock) and Maryland ($1.55M total, $400k cash + note + stock)
- Post-transaction, ultimate sellers hold ~1.0% of Vireo on a fully diluted basis
- Sellers include non-compete covenants for 3-5 years in broad restricted area
- Market consensus is 0% bullish (3 hold, 4 sell, 2 strong sell)
Financial Impact
Total purchase consideration of ~$13.66M in convertible notes plus assumption of ~$30.35M in debt (total ~$44M). Convertible note interest rate 3.85%. Conversion at $0.62/share would add ~22M shares (pre-consolidation). CEO's affiliate holds $22M senior secured loan.
Risk Factors
- Significant debt load (~$30M assumed + $13.66M convertible notes) with no disclosed revenue from acquired business
- Insider conflict: CEO John Mazarakis is a partner at Chicago Atlantic Group, which holds the $22M senior secured loan
- Convertible notes create future dilution; full conversion adds ~22M shares (~1% fully diluted currently but could increase with adjustments)
- Dispensary acquisitions subject to regulatory approvals — not guaranteed to close
- Historical performance on VREOF shows poor win rate (33% at T+20, avg -5.14%) — market skepticism persists
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-072936 |
| Document: tm2617497d2_ex4-1.htm | 0001104659-26-072936 |
| Document: tm2617497d2_8k.htm | 0001104659-26-072936 |
| Document: tm2617497d2_ex99-1.htm | 0001104659-26-072936 |
| Document: 0001104659-26-072936-index-headers.html | 0001104659-26-072936 |
| Document: 0001104659-26-072936-index.html | 0001104659-26-072936 |
| Document: 0001104659-26-072936.txt | 0001104659-26-072936 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 6w ago | 8-K | $10.97 $12.11 | ▲ +10.39% | ▲ +11.91% | $9.61 (−12.40%) |
Aug 11, 2026 7w ago | 8-K | $10.64 $12.12 | ▲ +13.91% | ▲ +14.97% | $9.61 (−9.68%) |
Aug 5, 2026 8w ago | 8-K | $10.01 $10.84 | ▲ +8.29% | ▲ +7.69% | $9.61 (−4.00%) |
Jul 30, 2026 9w ago | 8-K | $9.44 $10.60 | ▲ +12.29% | ▲ +9.30% | $9.61 (+1.80%) |
Jul 27, 2026 9w ago | 8-K | $9.70 $10.89 | ▲ +12.27% | ▲ +8.97% | $9.61 (−0.93%) |
Jun 18, 2026 15w ago | 8-K | $10.42 $9.80 | ▼ −5.95% | ▼ −5.64% | $9.61 (−7.77%) |
Jun 11, 2026 16w ago | 8-K | $12.46 $10.02 | ▼ −19.58% | ▼ −20.84% | $9.61 (−22.87%) |
Jun 9, 2026 16w ago | 8-K | $12.90 $9.82 | ▼ −23.88% | ▼ −27.77% | $9.61 (−25.50%) |
May 29, 2026 18w ago | 8-K | $13.05 $9.99 | ▼ −23.47% | ▼ −22.17% | $9.61 (−26.34%) |
May 12, 2026 20w ago | 8-K | $12.09 $12.90 | ▼ −6.70% | ▼ −8.43% | $9.61 (+20.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access